2.1
Pembrolizumab (Keytruda, Merck Sharp & Dohme) plus chemotherapy with or without bevacizumab is indicated for 'the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD‑L1 with a CPS ≥ 1'.
2 Information about pembrolizumab
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for pembrolizumab.
Price
2.3
The list price is £2,630.00 per 100 mg/4 ml concentrate for solution for infusion vial (excluding VAT; BNF online accessed October 2023).
2.4
The company has a commercial arrangement. This makes pembrolizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.